Traumatic Injury Clinical Trial Evaluating Tranexamic Acid in Children: An Efficacy Study

Hemorrhage Clinical Trial

— TIC-TOC  

Official title:

Traumatic Injury Clinical Trial Evaluating Tranexamic Acid in Children (TIC-TOC): An Efficacy Study

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT04387305
• Other study ID #: 128206
• Status: Not yet recruiting
• Phase: Phase 3
• Start date: October 1, 2024
• Est. completion date: March 31, 2030

Study information

• Verified date: November 2023
• Source: University of California, Davis
• Contact: Daniel K Nishijima, MD, MAS
• Phone: 916.734.3884
• Email: dnishijima[@]ucdavis.edu
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Trauma is the leading cause of death and disability in children in the United States. The objective of this study is to evaluate the benefits and harms of tranexamic acid (TXA; a drug that stops bleeding) in severely injured children with hemorrhagic brain and/or torso injuries. Using thromboelastography, we will measure baseline fibrinolysis to assess for treatment effects of TXA at different levels of fibrinolysis.

Description:

The TIC-TOC efficacy trial is a multicenter, adaptive allocation, randomized controlled trial of children younger than 18 years with hemorrhagic injuries to the torso and/or brain to evaluate the efficacy of TXA on functional outcome as measured by the PedsQL. Children will be randomized to one of three arms: 1) TXA 15 mg/kg bolus over 30 minutes, followed by a 2 mg/kg/hr infusion over 8 hours), 2) TXA 30 mg/kg bolus over 30 minutes, followed by a 4 mg/kg/hr infusion over 8 hours), and 3) normal saline placebo. A third TXA dose (45 mg/kg bolus dose over 30 minutes, followed by a 6 mg/kg/hr infusion over 8 hours) may be added later in the trial if a dose effect based on accumulating data is noted. The trial will be conducted in the Pediatric Emergency Care Applied Research Network (PECARN) across 40 sites over 4 years of enrollment for a maximum sample size of 2000 patients. A Bayesian adaptive randomization design will be used to evaluate the efficacy of TXA in children with hemorrhagic brain and/or torso injuries. Because different types of injury have different pathophysiology and potential response to TXA, three different injury strata will be evaluated: isolated hemorrhagic brain injury, isolated hemorrhagic torso injury, and both hemorrhagic brain and torso injuries. The efficacy of TXA will be analyzed across all enrolled children as well as across each type of injury. The Bayesian adaptive trial design also efficiently evaluates the effectiveness of TXA across different TXA doses. The trial will randomize the first 500 patients to two doses of TXA and placebo at a fixed 1:1:1 ratio. Interim analyses will be conducted when 500, 750, 1000, 1250, 1500, and 1750 patients have been enrolled. At each interim analysis, randomization probabilities will be adjusted in order to preferentially allocate patients to better performing doses, while allocation to the placebo arm will stay fixed. The adaptive randomization will be based entirely on pre-planned rules using accumulating data. A Bayesian hierarchical model will be used to estimate the treatment effect for each of the injury types to be informed by the data accumulated from all injury types. At interim analyses, if a dose effect is noted towards the higher dose of TXA (30 mg/kg bolus then a 4 mg/kg/hr infusion) being more efficacious using pre-specified criteria, then a higher dose study arm (TXA 45 mg/kg bolus then a 6 mg/kg/hr infusion) will be opened later in the trial. If the dose response curve is flat, suggesting that TXA is ineffective, then futility stopping rules can end the trial early.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 2000
• Est. completion date: March 31, 2030
• Est. primary completion date: March 31, 2030
• Accepts healthy volunteers: No
• Gender: All
• Age group: 0 Years to 17 Years

Eligibility

Inclusion Criteria:

1. Less than 18 years old AND

2. Penetrating torso trauma, blunt torso trauma, or head trauma as defined below:

3. Penetrating Torso Trauma:

a. Penetrating trauma to the chest, abdomen, neck, or pelvis with at least one of the

following:

• age-adjusted hypotension, or
• age-adjusted tachycardia despite adequate resuscitation fluids, or
• radiographic evidence of internal hemorrhage, or
• clinician suspicion of ongoing internal hemorrhage

4. Blunt Torso Trauma:

1. Clinician suspicion of hemorrhagic blunt torso injury and at least one of the

following:

• age-adjusted hypotension, or
• age-adjusted tachycardia despite adequate resuscitation fluids

2. Hemothorax on chest tube placement or imaging,

3. Clinical suspicion of hemorrhagic blunt torso injury and Intraperitoneal fluid on abdominal ultrasonography (Focused Assessment with Sonography in Trauma),

4. Intra-abdominal injury on CT with either contrast extravasation or more than trace intraperitoneal fluid,

5. Pelvic fracture with contrast extravasation or hematoma on abdominal/pelvic CT

scan with at least one of the following:

• Age-adjusted hypotension, or
• Age-adjusted tachycardia.

5. Head Trauma:

1. Initial Glasgow Coma Scale (GCS) score 3 to 13 with associated intracranial hemorrhage on cranial CT scan (enroll after cranial CT scan)

Exclusion Criteria:

• Unable to administer study drug within 3 hours of traumatic event
• Known pregnancy
• Known ward of the state
• Cardiac arrest prior to randomization
• GCS score of 3 with bilateral unresponsive pupils
• Isolated subarachnoid hemorrhage, epidural hematoma, or diffuse axonal injury
• Known venous or arterial thrombosis
• Known bleeding/clotting disorders
• Known seizure disorders
• Known history of severe renal impairment
• Known allergy to TXA
• Unknown time of injury (includes suspected non-accidental trauma)
• Previous enrollment into the TIC-TOC trial
• Prior TXA for current injury
• Prior opt-out
• Non-English and non-Spanish speaking

Related Conditions & MeSH terms

• Brain Injuries
• Brain Injuries, Traumatic
• Hemorrhage
• Trauma Injury
• Wounds and Injuries
• Wounds and Injury

Intervention

Drug:
• Tranexamic acid injection
Active drug is provided to participants as described based on the TXA arm they are randomized to.

Locations

Country	Name	City	State
n/a

Sponsors (2)

Lead Sponsor	Collaborator
Daniel Nishijima, MD, MAS	Pediatric Emergency Care Applied Research Network

References & Publications (3)

Nishijima DK, Gosdin M, Naz H, Tancredi DJ, Hewes HA, Myers SR, Stanley RM, Adelson PD, Burd RS, Finkelstein Y, VanBuren J, Casper TC, Kuppermann N; TIC-TOC Collaborators of the Pediatric Emergency Care Applied Research Network (PECARN). Assessment of pri — View Citation

Powers PE, Shore KK, Perez S, Ritley D, Kuppermann N, Holmes JF, Tzimenatos LS, Shawargga H, Nishijima DK. Public Deliberation as a Novel Method for an Exception From Informed Consent Community Consultation. Acad Emerg Med. 2019 Oct;26(10):1158-1168. doi: — View Citation

Trappey AF 3rd, Thompson KM, Kuppermann N, Stephenson JT, Nuno MA, Hewes HA, Meyers SR, Stanley RM, Galante JM, Nishijima DK; Traumatic Injury Clinical Trial Evaluating Tranexamic Acid in Children (TIC-TOC) Collaborators of the Pediatric Emergency Care Ap — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Glasgow Outcome Scale-Extended (GOS-E) Peds	Global functioning as measured on an 8-point scale (8-death, 7-vegetative state, 6-lower severe disability, 5-upper severe disability, 4-lower moderate disability, 3-upper moderate disability, 2-lower good recovery, 1-upper good recovery)	1 week, 1 month, 3 months, and 6 months
Other	Pediatric Quality of Life Inventory (PedsQL) Multidimensional Fatigue Scale	Fatigue and cognitive function; 0 to 100 with higher scores representing better outcomes	1 week, 1 month, 3 months, and 6 months
Other	D-dimer	Measure clot breakdown (ng/mL)	Change from baseline to end of 8-hour study drug infusion
Other	Plasmin-antiplasmin (PAP) complex	Measure fibrinolytic activity (mcg/L)	Change from baseline to end of 8-hour study drug infusion
Other	Tissue plasminogen activator (tPA)	Measure fibrinolytic activity (ng/mL)	Change from baseline to end of 8-hour study drug infusion
Other	Thrombosis	Any venous or arterial thrombosis on standard diagnostic imaging post-randomization	1 week or at hospital discharge (whichever comes first)
Other	Seizure	Clinical or electroencephalogram-documented seizure	1 week or at hospital discharge (whichever comes first)
Other	Behavior Rating Inventory of Executive Function (BRIEF)	Measurement of executive function after traumatic brain injury	6 and 12 months after injury
Primary	Pediatric Quality of Life Inventory (PedsQL) area under the curve	Neurocognitive functioning and quality-of-life measure; 0 to 100 with higher scores representing better outcomes	1 week, 1 month, 3 months, and 6 months (as measured as an area under the curve)
Secondary	Intracranial hemorrhage progression	Intracranial hemorrhage progression on cranial computed tomography imaging	24 hours (±6 hours)
Secondary	Blood transfusion	Total volume of packed red blood cells, platelets, fresh frozen plasma, and cryoprecipitate	First 48 hours after randomization
Secondary	PedsQL Physical Domain area under the curve	Physical domain of the PedsQL measure; 0 to 100 with higher scores representing better outcomes	1 week, 1 month, 3 months, and 6 months

External Links

•   TIC-TOC trial website